[1]单莉平,刘倩,宋琼,等.放射治疗与肿瘤疫苗联合在肿瘤治疗中的应用研究进展[J].陕西医学杂志,2025,54(8):1141-1144,1149.[doi:DOI:10.3969/j.issn.1000-7377.2025.08.026]
　SHAN Liping,LIU Qian,SONG Qiong,et al.Research progress on the application of radiotherapy combined with tumor vaccines in cancer treatment[J].,2025,54(8):1141-1144,1149.[doi:DOI:10.3969/j.issn.1000-7377.2025.08.026]
点击复制

放射治疗与肿瘤疫苗联合在肿瘤治疗中的应用研究进展

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年8期
页码:
1141-1144,1149
栏目:
综 述
出版日期:
2025-08-05

文章信息/Info

Title:
Research progress on the application of radiotherapy combined with tumor vaccines in cancer treatment
作者:
单莉平; 刘倩; 宋琼; 陈佩娟; 董忠谊
（南方医科大学南方医院放疗科，广东 广州 510515）
Author(s):
SHAN Liping; LIU Qian; SONG Qiong; CHEN Peijuan; DONG Zhongyi
（Department of Radiotherapy,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China）
关键词:
肿瘤疫苗; 放射治疗; 联合治疗; 肿瘤微环境; 免疫反应
Keywords:
Tumor vaccines; Radiotherapy; Combined therapy; Tumor microenvironment; Immune response
分类号:
R 730.5
DOI:
DOI:10.3969/j.issn.1000-7377.2025.08.026
文献标志码:
A
摘要:
肿瘤疫苗是能够引发针对特定肿瘤特异性免疫反应的疫苗，能够治疗或预防癌症的发生。尽管肿瘤疫苗显示出巨大潜力，但仍存在诸多挑战，且随着肿瘤进展可能释放出抑制免疫细胞功能的分子。因此，将肿瘤疫苗与其他治疗方法联合可能是最佳策略。放射治疗作为肿瘤治疗中的重要手段，可影响肿瘤微环境，促进机体免疫应答，并诱导肿瘤新抗原表达，对全身系统性免疫调控起到关键作用。研究发现，放射治疗与肿瘤疫苗联合具有协同作用，可显著提高抗肿瘤效果。放疗能够诱导全身性免疫反应，而肿瘤疫苗则在启动和维持患者的抗肿瘤免疫中发挥关键作用。目前，越来越多的研究致力于探索将不同类型的疫苗与放疗相结合，以深化肿瘤免疫学研究并优化肿瘤治疗效果。现对肿瘤疫苗分类、放射治疗与肿瘤疫苗联合治疗的研究进展、两者联合在肿瘤治疗中的应用以及联合治疗的应用前景进行综述。
Abstract:
Tumor vaccines are vaccines that can induce specific tumor-specific immune responses and can be used to treat or prevent the occurrence of cancer.Although tumor vaccines show great potential,there are still many challenges,and molecules that inhibit the function of immune cells may be released with the progression of tumors.Therefore,combining tumor vaccines with other treatment methods may be the best strategy.Radiotherapy,as an important means of tumor treatment,can affect the tumor microenvironment,promote the body’s immune response,and induce the expression of tumor neoantigens,playing a key role in systemic immune regulation.Studies have found that the combination of radiotherapy and tumor vaccines has a synergistic effect and can significantly improve the anti-tumor effect.Radiotherapy can induc0e systemic immune responses,while tumor vaccines play a key role in initiating and maintaining the patient’s anti-tumor immunity.At present,more and more studies are committed to exploring the combination of different types of vaccines with radiotherapy to deepen the research of tumor immunology and optimize the treatment effect of tumors.This article reviews the classification of tumor vaccines,the research progress of the combined treatment of radiotherapy and tumor vaccines,the application of the combination of the two in tumor treatment,and the application prospects of combined treatment.

参考文献/References:

[1]CRAIG D J,NANAVATY N S,DEVANABOYINA M,et al.The abscopal effect of radiation therapy[J].Future Oncol,2021,17(13)：1683-1694.
[2]XIE N,SHEN G,GAO W,et al.Neoantigens：Promising targets for cancer therapy[J].Signal Transduct Target Ther,2023,8(1)：9.
[3]郭家毓,呼群.小细胞肺癌免疫治疗研究进展[J].陕西医学杂志,2023,52(1)：118-120.
[4]GUO S,YAO Y,TANG Y,et al.Radiation-induced tumor immune microenvironments and potential targets for combination therapy[J].Signal Transduct Target Ther,2023,8(1)：205.
[5]DONLON N E,POWER R,HAYES C,et al.Radiotherapy,immunotherapy,and the tumour microenvironment：Turning an immunosuppressive milieu into a therapeutic opportunity[J].Cancer Lett,2021,502：84-96.
[6]MA S,HU K,XUE J,et al.Self-assembly nanoparticles potentiate in-situ tumor vaccine of radiotherapy by regulating tumor immunogenicity and tumor-associated macrophages[J].Chem Eng J,2024,497：154663.
[7]ZHANG Y,HUANG R,JIANG Y,et al.The role of bacteria and its derived biomaterials in cancer radiotherapy[J].Acta Pharm Sin B,2023,13(10)：4149-4171.
[8]YU T,YANG W,YAO S,et al.STING promotes intestinal IgA production by regulating acetate-producing bacteria to maintain host-microbiota mutualism[J].Inflamm Bowel Dis,2023,29(6)：946-959.
[9]HUANG R X,ZHOU P K.DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer[J].Signal Transduct Target Ther,2020,5(1)：60.
[10]LI Q,ZENG H,LIU T,et al.A dendritic cell vaccine for both vaccination and neoantigen-reactive T cell preparation for cancer immunotherapy in mice[J].Nat Commun,2024,15(1)：10419.
[11]FAN T,ZHANG M,YANG J,et al.Therapeutic cancer vaccines：Advancements,challenges and prospects[J].Signal Transduct Target Ther,2023,8(1)：450.
[12]GAO T,CEN Q,LEI H.A review on development of MUC1-based cancer vaccine[J].Biomed Pharmacother,2020,132：110888.
[13]GABBA A,ATTARIYA R,BEHREN S,et al.MUC1 glycopeptide vaccine modified with a GalNAc glycocluster targets the macrophage galactose C-type lectin on dendritic cells to elicit an improved humoral response[J].J Am Chem Soc,2023,145(24)：13027-13037.
[14]ZHOU S,FAN C,ZENG Z,et al.Clinical and immunological effects of p53-targeting vaccines[J].Front Cell Dev Biol,2021,9(11)：762796.
[15]ZHANG S,XIONG X,SUN Y.Functional characterization of SOX2 as an anticancer target[J].Signal Transduct Target Ther,2020,5(1)：135.
[16]WU Z,YANG M,CAO Y.Tumor antigens and vaccines in colorectal cancer[J].Med Drug Discov,2022,16：100144.
[17]RAASTOGI I,MURALIDHAR A,MCNEEL D G.Vaccines as treatments for prostate cancer[J].Nat Rev Urol,2023,20(9)：544-559.
[18]ZHAO X,ZHANG Y,TREJO-CERRO O,et al.A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity[J].NPJ Vaccines,2024,9(1)：119.
[19]EHSASATVATAN M,BAGHBAN K B,et al.Designing and immunomolecular analysis of a new broad-spectrum multiepitope vaccine against divergent human papillomavirus types[J].PLoS One,2024,19(12)：e0311351.
[20]GETU A A,TIGABU A,ZHOU M,et al.New frontiers in immune checkpoint B7-H3 (CD276) research and drug development[J].Mol Cancer,2023,22(1)：43.
[21]SYED ALTAF R R,MOHAN A,PALANI N,et al.A review of innovative design strategies：Artificial antigen presenting cells in cancer immunotherapy[J].Int J Pharm,2024,669：125053.
[22]PATIN E C,NENCLARES P,CHAN WAH HAK C,et al.Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy[J].Nat Commun,2024,15(1)：6923.
[23]ZHOU Z,DENG H,YANG W,et al.Early stratification of radiotherapy response by activatable inflammation magnetic resonance imaging[J].Nat Commun,2020,11(1)：3032.
[24]HOSEIN A N,DOUGAN S K,AGUIRRE A J,et al.Translational advances in pancreatic ductal adenocarcinoma therapy[J].Nat Cancer,2022,3(3)：272-286.
[25]AHMAD A,KHAN P,REHMAN A U,et al.Immunotherapy：An emerging modality to checkmate brain metastasis[J].Mol Cancer 2023,22(1)：111.
[26]KHIABANI N A,DOUSTVANDI M A,STORY D,et al.Glioblastoma therapy：State of the field and future prospects[J].Life Sci,2024,359(12)：123227.
[27]ROCHA PINHEIRO S L,LEMOS F F B,MARQUES H S,et al.Immunotherapy in glioblastoma treatment：Current state and future prospects[J].World J Clin Oncol,2023,14(4)：138-159.
[28]金龙,于娇,刘瑞廷,等.同步加量放射治疗在直肠癌新辅助放化疗中的临床效果观察[J].陕西医学杂志,2024,53(9)：1220-1223,1227.
[29]SHANG Q,ZHANG P,LEI X,et al.Insights into CSF-1/CSF-1R signaling：The role of macrophage in radiotherapy[J].Front Immunol,2025,16(2)：1530890.
[30]AN R,WU C,TANG C,et al.Blockade of CD73 potentiates radiotherapy antitumor immunity and abscopal effects via STING pathway[J].Cell Death Discov,2024,10(1)：404.
[31]HUANG R,ZHOU P K.HIF-1 signaling：A key orchestrator of cancer radioresistance[J].Radiat Med Prot,2020,1(1)：7-14.

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82272820）
更新日期/Last Update: 2025-08-04